Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2015 2
2016 1
2017 1
2018 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells.
Inaba A, Tuong ZK, Zhao TX, Stewart AP, Mathews R, Truman L, Sriranjan R, Kennet J, Saeb-Parsy K, Wicker L, Waldron-Lynch F, Cheriyan J, Todd JA, Mallat Z, Clatworthy MR. Inaba A, et al. Among authors: kennet j. Nat Commun. 2023 Apr 12;14(1):2071. doi: 10.1038/s41467-023-37424-w. Nat Commun. 2023. PMID: 37045832 Free PMC article.
Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.
Golubic R, Kennet J, Parker V, Robertson D, Luo D, Hansen L, Jermutus L, Ambery P, Ryaboshapkina M, Surakala M, Laker RC, Venables M, Koulman A, Park A, Evans M. Golubic R, et al. Among authors: kennet j. Diabetes Obes Metab. 2024 Jul;26(7):2634-2644. doi: 10.1111/dom.15579. Epub 2024 Apr 1. Diabetes Obes Metab. 2024. PMID: 38562018 Clinical Trial.
Sumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double-blinded placebo-controlled cross-over trial.
Golubic R, Hussein Ismail M, Josipovic M, Kennet J, Galderisi A, Evans ML. Golubic R, et al. Among authors: kennet j. Diabetes Obes Metab. 2023 Oct;25(10):3059-3063. doi: 10.1111/dom.15176. Epub 2023 Jun 13. Diabetes Obes Metab. 2023. PMID: 37312648 Clinical Trial.
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.
Seelig E, Howlett J, Porter L, Truman L, Heywood J, Kennet J, Arbon EL, Anselmiova K, Walker NM, Atkar R, Pekalski ML, Rytina E, Evans M, Wicker LS, Todd JA, Mander AP, Bond S, Waldron-Lynch F. Seelig E, et al. Among authors: kennet j. JCI Insight. 2018 Oct 4;3(19):e99306. doi: 10.1172/jci.insight.99306. JCI Insight. 2018. PMID: 30282826 Free PMC article. Clinical Trial.
Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.
Cutler AJ, Oliveira J, Ferreira RC, Challis B, Walker NM, Caddy S, Lu J, Stevens HE, Smyth DJ, Pekalski ML, Kennet J, Hunter KMD, Goodfellow I, Wicker LS, Todd JA, Waldron-Lynch F. Cutler AJ, et al. Among authors: kennet j. Wellcome Open Res. 2017 Oct 5;2:28. doi: 10.12688/wellcomeopenres.11300.3. eCollection 2017. Wellcome Open Res. 2017. PMID: 28815218 Free PMC article.
Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).
Heywood J, Evangelou M, Goymer D, Kennet J, Anselmiova K, Guy C, O'Brien C, Nutland S, Brown J, Walker NM, Todd JA, Waldron-Lynch F. Heywood J, et al. Among authors: kennet j. Trials. 2015 Mar 11;16:86. doi: 10.1186/s13063-015-0583-7. Trials. 2015. PMID: 25881192 Free PMC article. Clinical Trial.
Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study.
Truman LA, Pekalski ML, Kareclas P, Evangelou M, Walker NM, Howlett J, Mander AP, Kennet J, Wicker LS, Bond S, Todd JA, Waldron-Lynch F. Truman LA, et al. Among authors: kennet j. BMJ Open. 2015 Dec 8;5(12):e009799. doi: 10.1136/bmjopen-2015-009799. BMJ Open. 2015. PMID: 26646829 Free PMC article. Clinical Trial.
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
Todd JA, Evangelou M, Cutler AJ, Pekalski ML, Walker NM, Stevens HE, Porter L, Smyth DJ, Rainbow DB, Ferreira RC, Esposito L, Hunter KM, Loudon K, Irons K, Yang JH, Bell CJ, Schuilenburg H, Heywood J, Challis B, Neupane S, Clarke P, Coleman G, Dawson S, Goymer D, Anselmiova K, Kennet J, Brown J, Caddy SL, Lu J, Greatorex J, Goodfellow I, Wallace C, Tree TI, Evans M, Mander AP, Bond S, Wicker LS, Waldron-Lynch F. Todd JA, et al. Among authors: kennet j. PLoS Med. 2016 Oct 11;13(10):e1002139. doi: 10.1371/journal.pmed.1002139. eCollection 2016 Oct. PLoS Med. 2016. PMID: 27727279 Free PMC article. Clinical Trial.